A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE

A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE

Bibliographic Details
Main Authors:	Naohisa Ichiki, Toshiaki Tanabe, Satoko Hisada, Miho Sugata, Yumi Ito, Tomonori Komatsu, Masanori Kodera
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Journal of Cutaneous Immunology and Allergy
Online Access:	https://doi.org/10.1002/cia2.12157

Similar Items

Psoriasiform eruption on the face and extremities associated with nivolumab therapy
by: Amit Om, MD, et al.
Published: (2018-05-01)

Readministration of adenoviral gene delivery to dopamine neurons.
by: Gonzalez, S, et al.
Published: (2007)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
by: Alexander Batista-Duharte, et al.
Published: (2023-05-01)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
by: Aanika Balaji, et al.
Published: (2020-06-01)

Apremilast
by: Nihal Kundakçı
Published: (2022-04-01)

B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
by: Jyoti Rana, et al.
Published: (2024-03-01)

A case of malignant melanoma with shrinking metastases after sequential severe irAEs
by: Aya Maekawa, et al.
Published: (2020-04-01)

Psoriasiform Keratosis - Case report
by: Carla Andréa Avelar Pires, et al.
Published: (2014-04-01)

Successful Readministration of AAV8 Following Administration of Nondepleting CD4 Antibody at the Time of Vector Administration
by: McIntosh, J, et al.
Published: (2006)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
by: Yi-Shan Teng, et al.
Published: (2023-07-01)

Clinico-histomorphological study of psoriasis and Psoriasiform dermatitis
by: Shagun Gupta, et al.
Published: (2023-07-01)

Psoriasiform Dermatitis in a COVID-19 Patient
by: Marlyn Wu, et al.
Published: (2022-01-01)

Long-standing psoriasiform plaque over the leg
by: R Vignesh Narayan, et al.
Published: (2022-01-01)

1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors
by: Evan J Lipson, et al.
Published: (2023-11-01)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
by: Saeed Moradian, et al.
Published: (2023-06-01)

Apremilast for lithium-associated psoriasis
by: Joohyung Youh, et al.
Published: (2022-01-01)

Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016-09-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
by: Brian W. Labadie, et al.
Published: (2019-11-01)

Case report: Treatment of psoriasiform dermatitis in patients with malignancy
by: Jinzhu Mao, et al.
Published: (2024-04-01)

A case of psoriasiform drug eruption caused by temozolomide
by: Tokuko Oguro, et al.
Published: (2022-10-01)

Psoriasiform rash after initiation of treatment with olanzapine and carbamazepine.
by: M. Abdelkefi, et al.
Published: (2023-03-01)

Relapsed angioimmunoblastic T-cell lymphoma presenting as psoriasiform dermatitis
by: Spencer McClure, MD, et al.
Published: (2023-03-01)

A case of psoriasiform syphilid (from clinical practice)
by: S. V. Koshkin, et al.
Published: (2017-08-01)

A case of psoriasiform graft-versus-host disease
by: Jinping HUANG, et al.
Published: (2022-06-01)

Safety of apremilast: risk of psychical disorders
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Is apremilast a treatment for SAPHO syndrome?
by: Ju Zhang, et al.
Published: (2024-12-01)

Apremilast is efficacious in refractory alopecia areata
by: Neha Taneja, et al.
Published: (2020-10-01)

Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01)

Treatment of pyoderma gangrenosum with apremilast monotherapy
by: Zachary A. Bordeaux, BS, et al.
Published: (2022-12-01)

Case of durvalumab‐induced annular psoriasiform dermatitis in lung cancer
by: Asako Ota, et al.
Published: (2022-10-01)

Ghrelin attenuates imiquimod‐induced psoriasiform skin inflammation in mice
by: Kazuma Kaneda, et al.
Published: (2019-12-01)

Ocrelizumab‐induced psoriasiform dermatitis: Case reports and review of the literature
by: Natalia Naranjo Guerrero, et al.
Published: (2023-12-01)

Mechanisms and Effects of Isorhamnetin on Imiquimod-Induced Psoriasiform Dermatitis in Mice
by: Chieh-Shan Wu, et al.
Published: (2022-12-01)

Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis
by: Kevin Fenix, et al.
Published: (2020-09-01)

Psoriasiform mycosis fungoides–cutaneous T-cell lymphoma in an African American
by: Austinn C. Miller, MD, et al.
Published: (2023-08-01)

Gain-of-function of TRPM4 predisposes mice to psoriasiform dermatitis
by: Daisuke Yamada, et al.
Published: (2022-10-01)

Psoriasiform lesions as a side effect of SGLT-2 therapy
by: Jakub Krzysztof Gałązka, et al.
Published: (2023-01-01)

Dermal vasculature in psoriasis and psoriasiform dermatitis: A morphometric study
by: Shilpa Gupta, et al.
Published: (2011-01-01)